Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Burning Rock Biotech ( (BNR) ) has provided an announcement.
On December 23, 2025, Burning Rock Biotech announced that all shareholder resolutions proposed at its 2025 annual general meeting held the same day were approved, reinforcing continuity in both its governance and audit oversight. Shareholders ratified the appointment of Ernst & Young Hua Ming LLP as auditor for the fiscal year ending December 31, 2025, re-elected Feng Deng and Licen Lisa Xu as directors, and authorized the board to take all necessary actions to implement these resolutions, steps that collectively signal stability in the company’s leadership and financial supervision for investors and other stakeholders.
The most recent analyst rating on (BNR) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Burning Rock Biotech stock, see the BNR Stock Forecast page.
Spark’s Take on BNR Stock
According to Spark, TipRanks’ AI Analyst, BNR is a Neutral.
Burning Rock Biotech’s overall stock score is primarily influenced by its technical analysis, which shows positive momentum. However, significant financial challenges and a negative valuation score due to ongoing losses and lack of dividend yield weigh down the overall score. The absence of earnings call insights and corporate events limits additional context for potential investors.
To see Spark’s full report on BNR stock, click here.
More about Burning Rock Biotech
Burning Rock Biotech Limited (NASDAQ: BNR) is a China-based precision oncology company specializing in the application of next generation sequencing (NGS) technology. Its business focuses on NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has progressed from proof-of-concept research into clinical validation, positioning the firm within the rapidly evolving molecular diagnostics and oncology screening markets.
Average Trading Volume: 46,474
Technical Sentiment Signal: Hold
Current Market Cap: $233.6M
See more data about BNR stock on TipRanks’ Stock Analysis page.